Spur Therapeutics
Spur Therapeutics is a clinical-stage biotechnology company developing AAV gene therapies for chronic diseases, anchored by avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, with additional programs in adrenomyeloneuropathy, GBA1 Parkinson's disease, and heart failure.
- Company typePrivate
- Founded2015
- HeadquartersStevenage, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Spur Therapeutics does
Spur Therapeutics, formerly Freeline Therapeutics, is a clinical-stage biotechnology company developing adeno-associated virus (AAV) gene therapies for chronic diseases. Founded in 2015 and headquartered in Stevenage, United Kingdom with an additional office in New York, the company rebranded in June 2024 alongside a $50 million corporate financing from Syncona and the acquisition of SwanBio Therapeutics. Its pipeline is anchored by avigbagene parvec (FLT201), a Phase 3 registrational-stage gene therapy candidate encoding a rationally engineered glucocerebrosidase variant (GCase85) delivered via a proprietary AAV capsid to liver cells for Gaucher disease type 1. Two additional programs — SBT101 for adrenomyeloneuropathy (Phase 1 PROPEL trial) acquired via SwanBio, and SPR301 for GBA1 Parkinson's disease using an AAV9 capsid currently in IND-enabling studies — extend the platform into CNS indications, and an early-stage research program targets severe chronic heart failure.
The company's underlying technology centers on optimized gene therapy components: a GCase85 enzyme with substantially extended half-life versus wild-type, enabling deeper tissue penetration including bone and lung; proprietary AAV capsids engineered for higher transduction efficiency at lower doses; and tissue-selective promoters. Spur has received orphan drug designation for FLT201 in both the U.S. and EU and reported two-year Phase 1/2 follow-up data in which all five evaluable patients discontinued standard enzyme replacement or substrate reduction therapy while maintaining stable or improved disease biomarkers.
Spur Therapeutics operates a pre-revenue clinical-stage business model. The company does not yet commercialize any product and has not publicly disclosed pricing. Future revenue is expected to derive from one-time commercialization of approved gene therapies, distributed initially through qualified clinical trial sites and, upon approval, through specialty treatment centers and specialty pharmacies. Manufacturing at scale is outsourced to CDMOs with FDA/EMA-compliant quality systems, while CMC and preclinical activities are retained in-house. The company engages in enterprise-style GTM: scientific conference presentations, investor relations outreach, and direct engagement with researchers, clinicians, patient advocacy groups, and global regulators to advance clinical programs.
Spur Therapeutics firmographics
Firmographics- Name
- Spur Therapeutics
- Legal name
- Spur Therapeutics Limited
- Website
- https://spurtherapeutics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Spur Therapeutics is a clinical-stage biotechnology company developing AAV gene therapies for chronic diseases, anchored by avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, with additional programs in adrenomyeloneuropathy, GBA1 Parkinson's disease, and heart failure.
- Ownership category
- akta.pro rank
Spur Therapeutics industry classification
Industry- Product category
- Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Neurology/CNS Gene Therapies (HLAAACAH), Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)
Keywords
Where Spur Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Stevenage
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Spur Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Gene Therapy Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing gene therapies for chronic diseases. Revenue will be generated through commercialization of approved gene therapy products once clinical trials are completed and regulatory approvals are obtained.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Spur Therapeutics product offering
Product offeringCore offering
Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus (AAV) gene therapies for chronic debilitating diseases. Its pipeline includes avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, SBT101 in Phase 1 for adrenoleukodystrophy, and SPR301 in IND-enabling studies for GBA1 Parkinson's disease. The company uses proprietary AAV capsids and a rationally engineered GCase85 enzyme to deliver single-dose, disease-modifying treatments.
Product overview
Spur Therapeutics is a clinical-stage biotechnology company developing gene therapies for chronic diseases. The company's portfolio includes three gene therapy candidates: avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, SBT101 in Phase 1 for adrenoleukodystrophy (AMN), and SPR301 in IND-enabling stage for GBA1 Parkinson's disease. Additionally, the company has an early-stage program in severe chronic heart failure. All candidates use AAV-based delivery systems with engineered enzymes (GCase85) designed for improved stability and tissue penetration. The company was formerly known as Freeline and rebranded in June 2024 after acquiring SwanBio Therapeutics.
Differentiator
Problem solved
Functional benefit
Products and services
- Avigbagene parvec (FLT201) Clinical-stage AAV gene therapy candidate for Gaucher disease type 1 encoding a rationally engineered GCase85 enzyme variant with increased half-life. Designed as a one-time treatment to potentially stop or reverse disease progression by delivering sustained GCase enzyme expression via an AAV capsid to liver cells.
- SBT101 Gene therapy candidate for X-linked adrenoleukodystrophy (adrenomyeloneuropathy/AMN). Currently in Phase 1 clinical trial (PROPEL) evaluating safety in adult males.
- SPR301 Gene therapy development candidate for GBA1 Parkinson's disease. Uses AAV9 capsid to deliver rationally engineered GCase85 enzyme, demonstrating substantially higher GCase activity and greater alpha-synuclein reduction compared to wildtype GCase in preclinical studies.
- Severe Chronic Heart Failure Program Early-stage gene therapy research program leveraging cardioprotective proteins for cardiovascular diseases, targeting a severe subset of chronic heart failure to help stop disease progression.
Quantifiable outcome
- All five evaluable patients discontinued standard enzyme replacement or substrate reduction therapies while maintaining stable or improved disease biomarkers for over one year
- +3 more outcomes
Companies that use Spur Therapeutics
Customer profileSegments4 records
Ideal customer profiles2 records
Spur Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Spur Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- SwanBio TherapeuticscoreSpur Therapeutics acquired SwanBio Therapeutics, adding a gene therapy program for adrenoleukodystrophy (adrenomyeloneuropathy) and strengthening CNS expertise. This acquisition expanded the pipeline to include SBT101 program for AMN.
- Contract Development and Manufacturing Organizations (CDMOs)coreFor clinical and commercial supplies, Spur partners with CDMOs with quality systems compliant with FDA and EMA requirements. The company has in-house labs with CMC capabilities for preclinical drug development but outsources manufacturing at scale to external partners.
- Researchers and Clinicians WorldwideminorSpur works with researchers and clinicians around the world, peer companies in the healthcare industry, and patients and advocacy groups to advance gene therapy research and bring more impact to more people.
- Patients and Advocacy GroupsminorCollaborates with patients and advocacy groups as part of the company's mission to advance gene therapy and bring transformative medicines to patients who need them.
Scale indicators4 records
Recent moves8 records
Expansion highlights6 records
Spur Therapeutics competitors and assessment
Company assessmentDirect peers
- uniQure: uniQure is a clinical-stage gene therapy company developing AAV-based therapies for rare and CNS diseases, including a late-stage hemophilia B program. It is directly comparable to Spur in technology platform (AAV), clinical stage, and rare disease focus.
- Regenxbio: Regenxbio is a clinical-stage AAV gene therapy company with proprietary NAV Technology Platform for capsid delivery, advancing multiple internal and partnered programs across rare and prevalent diseases. It directly competes as an AAV platform peer.
- Sarepta Therapeutics: Sarepta is a commercial-stage gene therapy company with approved AAV-based products (Elevidys, Zolgensma) for Duchenne muscular dystrophy and spinal muscular atrophy. It is directly comparable in AAV gene therapy modality and rare disease focus, though more advanced commercially.
- Voyager Therapeutics: Voyager Therapeutics is a clinical-stage gene therapy company developing AAV-based therapies primarily for CNS diseases including Parkinson's and ALS, using proprietary capsid engineering. It is directly comparable in CNS AAV delivery and platform-based gene therapy approach.
- Taysha Gene Therapies: Taysha is a clinical-stage AAV gene therapy company focused on CNS and rare diseases, with multiple programs in clinical and preclinical development. It is comparable in AAV technology, clinical stage, and rare disease/CNS therapeutic focus.
- Lexeo Therapeutics: Lexeo Therapeutics is a clinical-stage gene therapy company developing AAV-based therapies for cardiovascular and CNS diseases. It is directly comparable given Spur's own cardiovascular program and CNS pipeline focus.
- Solid Biosciences: Solid Biosciences is a clinical-stage AAV gene therapy company developing treatments for Duchenne muscular dystrophy and other rare diseases. It is directly comparable in AAV technology platform, clinical stage, and rare disease focus.
- Prevail Therapeutics: Prevail Therapeutics was a clinical-stage AAV gene therapy company focused on neurodegenerative diseases (Parkinson's, GBA1 programs, lysosomal storage disorders) before being acquired by Eli Lilly. It is highly comparable to Spur's GBA1 Parkinson's program and lysosomal storage disease focus.
Broad incumbents
- BioMarin Pharmaceutical: BioMarin is a commercial-stage rare disease biotech with approved enzyme replacement therapies and a gene therapy pipeline including valoctocogene roxaparvovec for hemophilia A. It is a broader incumbent with overlapping rare disease expertise and gene therapy commercialization capabilities.
- Pfizer: Pfizer is a large pharmaceutical company with an active gene therapy portfolio (including Beqvez for hemophilia B) and significant rare disease infrastructure. Spur's CEO Michael Parini previously held senior global roles at Pfizer, and it represents a potential strategic partner or acquirer with overlapping therapeutic interests.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Spur Therapeutics social profiles
Digital presenceSpur Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spur Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
Spur Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spur Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spur Therapeutics
What does Spur Therapeutics do?
Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus (AAV) gene therapies for chronic debilitating diseases. Its pipeline includes avigbagene parvec (FLT201) in Phase 3 for Gaucher disease type 1, SBT101 in Phase 1 for adrenoleukodystrophy, and SPR301 in IND-enabling studies for GBA1 Parkinson's disease. The company uses proprietary AAV capsids and a rationally engineered GCase85 enzyme to deliver single-dose, disease-modifying treatments.
Is Spur Therapeutics a public or private company?
Spur Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Spur Therapeutics founded?
Spur Therapeutics was founded in 2015. It employs 101 to 250 people.
Where is Spur Therapeutics based?
Spur Therapeutics is headquartered in Stevenage, United Kingdom, in the Europe region.
How does Spur Therapeutics make money?
One revenue line is on record: gene Therapy Development and Commercialization.
Who are Spur Therapeutics's main competitors?
Direct peers on record are uniQure, Regenxbio, Sarepta Therapeutics, Voyager Therapeutics, Taysha Gene Therapies, Lexeo Therapeutics, Solid Biosciences and Prevail Therapeutics. Broad incumbents are BioMarin Pharmaceutical and Pfizer.
Does Spur Therapeutics have an API?
No public API is recorded for Spur Therapeutics.
What industry is Spur Therapeutics in?
Spur Therapeutics's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.